Literature DB >> 15524226

Outcome of treatment of multidrug resistant tuberculosis.

W V Senaratne1.   

Abstract

Multidrug resistant tuberculosis (MDRTB) is a growing problem worldwide. It is an emerging problem in Sri Lanka too although the exact data are not known. This report describes treatment and outcome of 14 MDRTB patients. All have had previous anti-tuberculosis treatment. Out of 32 previous treatment episodes, treatment has been either irregular or defaulted in 26(81%), which has largely contributed to the emergence of drug resistance. Treatment commenced with a combination of second line anti-tuberculosis drugs, namely, amikacin, ciprofloxacin, ethionamide, clofazimine and pyrazinamide. Four patients were considered cured, another four failed treatment, five defaulted treatment and one died. Previous sensitivity to second line drugs and proper isolation facilities were not available. Preparedness to face the threat of MDRTB is essential. Measures should be taken to reduce the rate of defaulters of anti-tuberculosis treatment, and facilities to treat MDRTB should be expanded.

Entities:  

Mesh:

Year:  2004        PMID: 15524226     DOI: 10.4038/cmj.v49i3.3246

Source DB:  PubMed          Journal:  Ceylon Med J        ISSN: 0009-0875


  4 in total

Review 1.  Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

Authors:  M Gopal; N Padayatchi; J Z Metcalfe; M R O'Donnell
Journal:  Int J Tuberc Lung Dis       Date:  2013-03-25       Impact factor: 2.373

2.  Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China.

Authors:  Qingfeng Wang; Yu Pang; Wei Jing; Yufeng Liu; Na Wang; Hongyun Yin; Qing Zhang; Zhizhong Ye; Min Zhu; Fujian Li; Ping Liu; Tingting Wu; Wei Chen; Wei Wu; Zhihua Qin; Chao Qiu; Qunyi Deng; Tao Xu; Jing Wang; Ru Guo; Yadong Du; Jun Wang; Hairong Huang; Xiaohong Chen; Naihui Chu
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

3.  Map the gap: missing children with drug-resistant tuberculosis.

Authors:  C M Yuen; C A Rodriguez; S Keshavjee; M C Becerra
Journal:  Public Health Action       Date:  2015-03-21

Review 4.  Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.

Authors:  Thomas J Hwang; Svetlana Dotsenko; Azizkhon Jafarov; Karin Weyer; Dennis Falzon; Kaspars Lunte; Paul Nunn; Ernesto Jaramillo; Salmaan Keshavjee; Douglas F Wares
Journal:  BMJ Open       Date:  2014-01-02       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.